164 reports of this reaction
3.4% of all SUCCINYLCHOLINE CHLORIDE reports
#3 most reported adverse reaction
CARDIAC ARREST is the #3 most commonly reported adverse reaction for SUCCINYLCHOLINE CHLORIDE, manufactured by Hospira, Inc.. There are 164 FDA adverse event reports linking SUCCINYLCHOLINE CHLORIDE to CARDIAC ARREST. This represents approximately 3.4% of all 4,806 adverse event reports for this drug.
Patients taking SUCCINYLCHOLINE CHLORIDE who experience cardiac arrest should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CARDIAC ARREST is moderately reported among SUCCINYLCHOLINE CHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to cardiac arrest, the following adverse reactions have been reported for SUCCINYLCHOLINE CHLORIDE:
The following drugs have also been linked to cardiac arrest in FDA adverse event reports:
CARDIAC ARREST has been reported as an adverse event in 164 FDA reports for SUCCINYLCHOLINE CHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
CARDIAC ARREST accounts for approximately 3.4% of all adverse event reports for SUCCINYLCHOLINE CHLORIDE, making it one of the most commonly reported side effect.
If you experience cardiac arrest while taking SUCCINYLCHOLINE CHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.